76 results on '"Chang, Sui-Yuan"'
Search Results
2. Targeting protein-protein interaction interfaces with antiviral N protein inhibitor in SARS-CoV-2
3. The emergence and successful elimination of SARS-CoV-2 dominant strains with increasing epidemic potential in Taiwan’s 2021 outbreak
4. Immunogenicity and safety of heterologous booster with protein-based COVID-19 vaccine (NVX-CoV2373) in healthy adults: A comparative analysis with mRNA vaccines
5. Weight and metabolic changes among virally suppressed people with HIV who switched to co-formulated bictegravir/emtricitabine/tenofovir alafenamide
6. Effectiveness of second-generation integrase strand-transfer inhibitor-based regimens for antiretroviral-experienced people with HIV who had viral rebound
7. Synthesis, evaluation, and mechanism of 1-(4-(arylethylenylcarbonyl)phenyl)-4-carboxy-2-pyrrolidinones as potent reversible SARS-CoV-2 entry inhibitors
8. Evolution of neutralizing antibodies and cross-activity against different variants of SARS-CoV-2 in patients recovering from COVID-19
9. Natural fucoidans inhibit coronaviruses by targeting viral spike protein and host cell furin
10. Correlation of adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations
11. Factors associated with viral rebound among COVID-19 patients receiving oral antivirals
12. Coexistent disseminated Kaposi's sarcoma and disseminated Mycobacterium avium complex infection in a patient with AIDS
13. Performance of two commercial multiplex polymerase chain reaction assays for the etiological diagnosis of sexually transmitted infections among men who have sex with men
14. Immunogenicity and safety of third-dose mRNA COVID-19 vaccines in healthy adults previously vaccinated with two doses of the ChAdOx1 vaccine
15. Serological response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 prime-boost vaccination with a twelve-week interval
16. Clinical assessment of SARS-CoV-2 infectivity by rapid antigen test compared with virus isolation
17. Risky sexual practices and hepatitis C viremia among HIV-positive men who have sex with men in Taiwan
18. Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan
19. Evolution of anti-SARS-CoV-2 spike protein titers after two-dose of COVID-19 vaccination among people living with HIV
20. Serological response after COVID-19 mRNA-1273 booster dose in immunocompromised patients, Taiwan, July to August 2021
21. SARS-CoV-2 infection among healthcare workers whom already received booster vaccination during epidemic outbreak of omicron variant in Taiwan
22. Virological responses to tenofovir-alafenamide-containing antiretroviral therapy in people living with HIV co-infected with lamivudine-resistant or lamivudine-susceptible hepatitis B virus
23. Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens
24. Incidence of low-level viremia and its impact on virologic failure among people living with HIV-1 who switched to elvitegravir-based antiretroviral therapy
25. Design, synthesis and biological evaluations of niclosamide analogues against SARS-CoV-2
26. Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination
27. Endolysosomal cation channels point the way towards precision medicine of cancer and infectious diseases
28. Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain
29. Prospective health surveillance for COVID-19 among health care workers at a university medical center in Taiwan, January to June 2020
30. Spatial and Temporal Origin of the Third SARS-CoV-2 Outbreak in Taiwan
31. Evolution of SARS-CoV-2 neutralizing antibody in an HIV-positive patient with COVID-19
32. High prevalence of sexually transmitted coinfections among at-risk people living with HIV
33. Seroepidemiology of the human herpesvirus 8 infection among people living with HIV in Taiwan, 2014–2018
34. Failure of pre-exposure prophylaxis with on-demand tenofovir disoproxil fumarate/emtricitabine resulting in emergence of antiretroviral resistance
35. A cross-sectional seroprevalence for COVID-19 among healthcare workers in a tertially care hospital in Taiwan
36. Experience of the use of hydroxychloroquine on patients with COVID-19: A perspective on viral load and cytokine kinetics
37. Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy
38. Measurement of uracil-DNA glycosylase activity by matrix assisted laser desorption/ionization time-of-flight mass spectrometry technique
39. Enhancement of the IFN-β-induced host signature informs repurposed drugs for COVID-19
40. Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects
41. Prolonged virus shedding even after seroconversion in a patient with COVID-19
42. Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 patients
43. A case of transient existence of SARS-CoV-2 RNA in the respiratory tract with the absence of anti-SARS-CoV-2 antibody response
44. The role of phylogenetic analysis in clarifying the infection source of a COVID-19 patient
45. Trends of recent hepatitis C virus infection among HIV-positive men who have sex with men in Taiwan, 2011–2018
46. Proofreading of single nucleotide insertion/deletion replication errors analyzed by MALDI-TOF mass spectrometry assay
47. Effectiveness of half-a-tablet efavirenz plus 2 nucleos(t)ide reverse-transcriptase inhibitors as maintenance therapy with the guidance of therapeutic drug monitoring among virologically suppressed HIV-positive patients: A prospective study
48. Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects
49. Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients
50. Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.